Central nervous system metastases in breast cancer patients administered trastuzumab

Area of Science:

• Oncology
• Pharmacology

Background:

• HER2/neu receptor over-expression occurs in 20-30% of invasive breast cancers, correlating with aggressive disease and poorer survival.
• Trastuzumab (Herceptin) improves outcomes in HER2/neu-positive advanced breast cancer by targeting the HER2/neu receptor.

Purpose of the Study:

• To discuss the pathophysiology and clinical implications of central nervous system (CNS) metastases in patients treated with trastuzumab.
• To explore reasons for trastuzumab's limited efficacy in the CNS despite systemic treatment success.

Main Methods:

• Review of existing literature on HER2/neu-positive breast cancer treatment and CNS metastasis patterns.
• Discussion of trastuzumab's pharmacokinetic properties, particularly its penetration into the CNS.
• Analysis of potential predisposing factors for CNS relapse in HER2/neu-positive patients.

Main Results:

• Trastuzumab significantly improves response rates, time to progression, and survival in HER2/neu-positive advanced breast cancer.
• Central nervous system (CNS) metastases represent a common failure site, even with effective extracerebral disease control.
• Limited trastuzumab penetration into the CNS due to its high molecular weight is a primary suspected cause for CNS relapse.

Conclusions:

• The high molecular weight of trastuzumab hinders its ability to cross the blood-brain barrier, leading to CNS metastases.
• Improved systemic control and prolonged survival may unmask or facilitate CNS relapse in HER2/neu-positive breast cancer.
• Further research is needed to understand the predisposition to brain metastases in HER2/neu-amplified cancers and develop strategies for CNS protection.